Search PubMed⌕ Search

Biomedical subjects

M Kawamura

Publications and source records attributed to M Kawamura.

At least 757 records · Page 42Linked to original sources
PubMed1987

Comparison of the effect of aminoglycosides on excretion of N-acetyl-beta-glucosaminidase.

Urinary N-acetyl-beta-glucosaminidase (NAG) activity was determined in ten patients receiving 200 mg of astromicin and ten patients receiving 100 mg of dibekacin; each dose was administered twice a day for five days. There was a significant difference between the aminoglycosides in the rate at which NAG activity increased, suggesting that astromicin has a lower nephrotoxicity.

Acetylglucosaminidase↗
PubMed1987

[The clinical effect of fosfomycin on cystitis].

Fosfomycin (FOM) is an antibiotic which inhibits phospho(enol)pyruvic acid transferase. Fifty-five patients with cystitis were treated with the drug for 7 days, at oral doses of 1 g for 3 times a day. Adult females under 70 years of age, visiting the clinic within 2 weeks after the onset, were classified as cases with typical simple cystitis with confirming the bladder irritability, pyuria and bacteriuria. The treatment was effective for 95.0% of these cases. Two cases with atypical cystitis caused by Klebsiella pneumoniae poorly responded to the drug.

Administration, Oral↗
PubMed1987

Salivary immunoreactive human epidermal growth factor (IR-hEGF) in patients with peptic ulcer disease.

EGF is reported to have a potent protective effect on peptic ulcer formation in rats. In this study, we measured the IR-hEGF concentrations in the saliva of normal human subjects and patients with peptic ulcer disease or non-peptic ulcer gastroduodenal disease. In normal subjects, the level of salivary IR-hEGF was highest in the early morning, and the values in individuals on different days showed small variations. There were no sex differences or age-related changes in the salivary IR-hEGF levels. The concentrations of the peptide were lower in patients in the active (0.96 +/- 26 ng/ml, mean +/- SE, n = 4) and healing stages (1.06 +/- 0.24 ng/ml, n = 8) of peptic ulcer disease as compared with those in normal subjects (3.19 +/- 0.46 ng/ml, n = 47). No significant differences in salivary IR-hEGF levels were observed between normal subjects and patients in the scaring stage of peptic ulcer disease (2.40 +/- 0.42 ng/ml, n = 21), or those with gastric cancer (2.44 +/- 0.27 ng/ml, n = 21) and atrophic or superficial gastritis (2.31 +/- 0.34 ng/ml, n = 28). Although the pathophysiological significance of these lower salivary IR-hEGF levels in patients with peptic ulcer disease is unclear, it is possible that the low level of hEGF in saliva may decrease the resistance of the mucosa to physicochemical stress, and thus participate in the development of the diseases.

Circadian Rhythm↗
PubMed1987

[Pharmacokinetics in neonates and infants following administration of amikacin].

Sixteen neonates (at ages of 8 to 28 days) and 8 infants (at ages of 35 days to 1 year), who were in need of treatment with amikacin sulfate, were subjected to the present study. The drug was administered by intramuscular route (1.39 to 3.13 mg/kg) or by intravenous drip infusion over a 30 to 60 minutes period (2.94 to 6.00 mg/kg). Blood levels and urinary excretion of the drug were investigated with these subjects. The blood levels were also analyzed according to pharmacokinetic models. 1. When the drug was administered intramuscularly to neonates at average doses of 1.49 and 2.96 mg/kg and to infants at average doses of 2.97 mg/kg peak levels of 2.74, 6.53 and 8.55 micrograms/ml, respectively, were attained at 30 minutes after dosing. 2. When the drug was administered to neonates at average doses of 3.01 and 5.89 mg/kg by intravenous drip infusion over a 30 to 60 minutes period and to infants at average doses of 2.97 and 6.00 mg/kg in the same manner, peak levels of 7.70, 20.9, 9.40 and 23.0 micrograms/ml, respectively, were attained at the end of the intravenous drip infusion. 3. Urinary levels and recovery rates tended to increase with ages of these subjects. Urinary recovery rates for the neonates and the infants were 41.0 and 58.9%, respectively, on the average. 4. From a pharmacokinetic analysis of blood levels of the drug, it was concluded that, in any of the subjects who received the drug intramuscularly or by intravenous drip infusion, it would be possible to use the one-compartment open model. In the subjects who received the drug by intravenous drip infusion, however, it was determined the two-compartment open model would be the choice. 5. In the neonates and the infants, whose blood levels were analyzed according to the one-compartment open model, Ka values averaged 7.51 and 6.62 hr-1, respectively, with respective average Kel values of 0.32 and 0.66 hr-1. Average Vd values obtained were 0.36 and 0.26 L/kg, respectively. There was a negative correlation between the Vd values and the ages of the subjects, while there was a positive correlation between the Kel values and the ages. 6. Appropriate conditions for administering the drug by intravenous drip infusion to neonates and infants at ages of more than 1 week were investigated taking observed blood levels and achieved peak levels and trough levels calculated using the one-compartment open model into account.(ABSTRACT TRUNCATED AT 400 WORDS)

Age Factors↗
PubMed1986

Structure of the extra-membranous domain of the beta-subunit of (Na,K)-ATPase revealed by the sequences of its tryptic peptides.

Membrane bound dog kidney (Na,K)-ATPase was digested with trypsin. The peptides that were recovered in the supernatant were purified and sequenced. By comparing these results with the sequence of alpha- and human beta-subunits, the location of each of the peptides could be allotted. Both accessibility to trypsin and the facility of release into the water phase indicated that these peptides were derived from the exposed surface of the intact enzyme. The sequence, GXGXXG, reported in the Torpedo californica beta-subunit [(1986) FEBS Lett. 196, 315-319] was likely a mere coincidence with the sequence of the dinucleotide-binding site, since the last glycine was replaced by proline in the sequence of the dog beta-subunit. A disulfide bridge was found within a peptide derived from the beta-subunit. A possible model for the beta-subunit structure is proposed.

Amino Acid Sequence↗
PubMed1986

A new restriction endonuclease from Spirulina platensis.

Three restriction endonucleases, Sp1I, Sp1II and Sp1III have been purified partially from Spirulina platensis subspecies siamese and named. Sp1I cleaves bacteriophage lambda DNA at one site, phi X 174 RF DNA at two sites, but does not cleave pBR322 DNA. This enzyme recognizes the sequence 5'CGTACG3' 3'GCATCG5' and cuts the site indicated by the arrows. Sp1II is an isoschizomer of Tth111I and Sp1III is an isoschizomer of HaeIII.

Base Sequence↗
PubMed1986

Primary structure of the beta-subunit of Torpedo californica (Na+ + K+)-ATPase deduced from the cDNA sequence.

DNA complementary to the Torpedo californica electroplax mRNA coding for the beta-subunit of (Na+ + K+)-ATPase has been cloned by screening a cDNA library with an oligodeoxyribonucleotide probe. Nucleotide sequence analysis of the cloned cDNA has revealed that this polypeptide consists of 305 amino acid residues (including the initiating methionine). The transmembrane topology and the potential N-glycosylation sites of this polypeptide are discussed.

Amino Acid Sequence↗